Sorafenib in Thyroid Cancer Patients: Learning From Toxicity

A recent review showed frequent reductions of sorafenib dose in the treatment of metastatic thyroid cancer because of toxicity consistent with the findings of the phase III DECISION trial and contrasting with the safety of sorafenib in other cancer populations. The unexpected excess of toxicity obse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Huillard, Olivier, Blanchet, Benoit, Boudou-Rouquette, Pascaline, Thomas-Schoemann, Audrey, Wassermann, Johanna, Goldwasser, François
Formato: Artigo
Idioma:Inglês
Publicado em: AlphaMed Press 2014
Assuntos:
Letters to the Editor
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4122476/
https://ncbi.nlm.nih.gov/pubmed/25052452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0156
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados